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S U M M A R Y
Background: Patients have been identiﬁed with hemorrhagic fever (HF) caused by Huaiyangshan virus
(HYSV) infection since 2009. This study aimed to investigate the characteristics of clinical symptoms,
laboratory examinations, epidemiological factors, and therapeutic responses in patients with
Huaiyangshan hemorrhagic fever (HYSHF).
Methods: A total of 57 patients with a suspected HF were admitted to the Department of Infectious
Diseases, the Afﬁliated Union Hospital of Tongji Medical College between June 2009 and October 2010. A
potential infection with HYSV was determined by indirect immunoﬂuorescent assay and reverse-
transcription (RT)-PCR. The clinical symptoms, epidemiological characteristics, laboratory examinations,
and therapeutic responses of these patients were evaluated.
Results: Forty-eight out of 57 patients were diagnosed with HYSHF. They displayed diverse clinical
symptoms, such as an acute febrile ﬂu-like illness, and progressed to proteinuria, hemorrhagic
manifestations, and encephalopathy. Some patients exhibited progressive leukopenia, thrombocytope-
nia, liver and kidney dysfunction, and systemic cell injury. Following symptom-speciﬁc treatment, 35
patients recovered completely and 13 patients died from severe complications, including central
nervous system manifestations.
Conclusions: Patients with HYSHF displayed diverse clinical symptoms and laboratory ﬁndings. Such
patients should be treated immediately and closely monitored to prevent severe complications.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Viral hemorrhagic fevers (VHFs) in animals and humans are
caused by infections with RNA viruses from the families
Arenaviridae, Filoviridae, Bunyaviridae, and Flaviviridae.1,2 Hantavi-
rus, Crimean-Congo hemorrhagic fever (CCHF) virus, and Rift
Valley fever (RVF) virus, in the Bunyaviridae family, can cause
severe HF in Asians and remain serious threats to human health.
These, together with new more recently discovered viruses, are a
great challenge to the prevention and treatment of VHF. In
addition, patients infected with some of these viruses can develop
severe complications that have a high mortality. Therefore,
recognition of new VHF-related viruses and their pathogenesis
in humans is of great signiﬁcance.
Previous studies have reported a new disease known as
Huaiyangshan hemorrhagic fever (HYSHF), also known as severe
fever with thrombocytopenia syndrome (SFTS), in the Huaiyang-
shan mountain region of Hubei and Henan, China.3,4 HYSHF is
caused by the Huaiyangshan virus (HYSV, also known as the severe* Corresponding author. Tel.: +86 27 85726135; fax: +86 27 85356369.
E-mail address: hyw581441@yahoo.com.cn (Y.-W. He).
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http://dx.doi.org/10.1016/j.ijid.2013.03.007fever with thrombocytopenia virus (SFTSV)), a novel member of
the Bunyaviridae family that is closely related to the viruses of the
genus Phlebovirus.3,4 There has been no systematic analysis of the
clinical and laboratory characteristics of patients with HYSHF.
Furthermore, it is unclear what the epidemiological features of
HYSV infection are in China.
This study aimed to investigate the epidemiological character-
istics that contribute to HYSV infection, clinical manifestations,
laboratory ﬁndings, and therapeutic responses of patients with
HYSHF in a Chinese population. We discuss the implications of our
ﬁndings.
2. Methods
2.1. Cases
A total of 57 patients with a suspected tick-borne disease were
referred to the Department of Infectious Diseases, the Afﬁliated
Union Hospital of Tongji Medical College, Wuhan, China between
June 2009 and October 2010. These patients had unexplained
fever (>37.5 8C), leukopenia (<4.0  109/l), thrombocytopenia
(<100  109/l), and multiple organ dysfunctions, but they had
no evidence of infection with hantaviruses, Leptospira, dengueses. Published by Elsevier Ltd. All rights reserved.
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cases fulﬁlled the prevention and care guidelines for SFTS of the
Ministry of Health, the People’s Republic of China (MOHC; 2010).5
Individuals with fever, leukopenia, or thrombocytopenia alone
were excluded from this study.
Written informed consent was obtained from conscious
patients or the relatives of unconscious patients. The experimental
protocols were established in accordance with the medical
research regulations of the Ministry of Health, China, and were
approved by the Ethics Committee of the Afﬁliated Union Hospital
of Tongji Medical Colleges.
2.2. Laboratory tests
Peripheral blood samples were obtained from individual
patients, and their blood cell counts with differential were
routinely examined at the Clinical Diagnosis Laboratory of the
Union Hospital. Plasma levels of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), lactate dehydrogenase (LDH),
and creatine kinase (CK) in individual patients were tested at the
Biochemistry Laboratory of the Union Hospital. Furthermore, the
activated partial thromboplastin time (APTT) and thrombin time
(TT) of fresh plasma samples from individual patients were
measured at the Clinical Diagnosis Laboratory of the Union
Hospital.
HYSV-speciﬁc immunoglobulin IgM and IgG antibodies and
HYSV-speciﬁc RNA in individual subjects were characterized by
immunoﬂuorescent assay (IFA) using HYSV-infected Vero-E6 cells
as antigens,3 and reverse-transcription (RT)-PCR,6 respectively, at
the National Institute for Communicable Disease Control and
Prevention, China Center for Disease Control and Prevention. The
levels of plasma IgM and IgG antibodies against Ehrlichia
chaffeensis were determined by IFA using E. chaffeensis (Arkansas
strain)-infected DH82 cells as antigens, as described previously.7
Similarly, hantavirus, Leptospira, dengue virus, CCHF virus, and
typhoid bacillus-speciﬁc antibodies in individual subjects were
analyzed by IFA.8
2.3. Treatments
All patients with HYSHF were treated with the same
basic protocol. First, the patients were provided with supportive
therapy daily to maintain the balance of the internal
environment, including vitamins and energy. Patients with
severe neutropenia (<2.0  109/l) were treated with 100 mg
granulocyte colony-stimulating factor (G-CSF) for 1–3 days.
Some patients were positively transfused with platelets and
treated with clotting factors. All patients were treated with
antibiotics (piperacillin 3.0–5.0 g per day, levoﬂoxacin 0.6 g per
day, or cephalosporins 2–4 g per day) to prevent secondary
bacterial infections. All patients were provided with doxycycline
(0.2–0.4 g per day) for at least 5 days to treat potential infections
with monocytic ehrlichiosis before the diagnosis. Some patients
were treated with appropriate hemostatic medicines, such as
vasopressin, somatostatin, oxytocin, and others, to terminate
bleeding and to prevent disseminated intravascular coagulation
(DIC). Moreover, some patients received oxygen masks with
positive pressure ventilation through a breathing machine if
they had shortness of breath, rapidly dropping oxygen satura-
tion, pulmonary edema, acute respiratory distress syndrome
(ARDS), or a concurrent lung infection. In addition, patients with
ARDS were treated with extracorporeal membrane oxygenation
(ECMO) therapy. Patients with heart failure were treated with
oxygen, nutrition, cardiac drugs, and digitalis, and patients with
kidney dysfunction were treated with diuretic drugs, improved
renal microcirculation, and kidney dialysis. Finally, a fewpatients with intracranial hemorrhages, convulsion, and coma
were treated with supportive medicines.
2.4. Data collection and analysis
Demographic and clinical data, medication/treatment history,
clinical course (including the number of days before seeking
medical attention), and clinical symptoms (such as fever,
headache, myalgia, nausea, malaise, pulmonary and hepatic
dysfunction, renal dysfunction, and neurological involvement),
were collected and evaluated. Physical ﬁndings, laboratory data,
time of defervescence, treatment, and mortality were observed.
Data are expressed as the number of cases and percentage, or the
median and range. These patients were stratiﬁed on the basis of
some of the measures for the analysis of mortality by Fisher’s exact
test; SPSS version 17.0 was used for the analysis (SPSS Inc., Chicago,
IL, USA). A two-tailed p-value of less than 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Diagnosis of patients with HYSVF
From June 2009 to October 2010, a total of 57 patients with
suspected VHF were referred to our hospital. Analysis for a
potential infection with HYSV revealed that 48 (84.2%) out of 57
subjects displayed positive serum anti-HYSV IgM; 37 out of 48
patients were positive for HYSV-speciﬁc RNA detection. However,
no blood samples from the patients were positive for serum
antibodies against E. chaffeensis, hantaviruses, Leptospira, dengue
virus, CCHF virus, or bacterium typhosum. These 48 patients were
diagnosed with HYSHF. Interestingly, among the remaining nine
patients with negative detection of HYSV, three were diagnosed
with lymphoma, four with Gram-negative bacterial septicemia,
and for two there was positive detection of blood cell coxsackie
virus RNA (data not shown).
3.2. Demographic characteristics and clinical epidemiology
There were 29 female patients (60%) and 19 male patients
(40%), and their mean age was 53.7  9.1 years. With the exception
of two cases, all of the patients were older than 40 years of age; no
patient was younger than 20 years of age. Analysis of the distribution
of these cases revealed that the patients came from an area
approximately 200 km around Wuhan City, Hubei Province, China.
These patients were transferred from local clinics in Caidian-qu
District of Wuhan City (one case), Xiaogan City (three cases), Suizhou
City (seven cases), Huanggang City (17 cases), Dawu County (four
cases) and Xianning City (two cases) (Hubei Province), and Xinyang
City (14 cases) (Henan Province), which are geographically con-
nected. The majority of cases occurred sporadically. The disease
appeared in May, and the numbers of cases reached a peak in June or
July, decreasing in August. All cases happened in rural hilly areas, and
many patients were elderly and young men with houses surrounded
by the bush. Forty-six out of 48 patients (95%) were farm workers. The
majority of patients worked in farming ﬁelds picking tea in the
mountains, or herding sheep, planting mushrooms, farming, etc.
Almost all patients had a history of animal contact or a recent tick
bite. There was no infection among attending health care workers and
the close relatives of patients. It would appear that the disease occurs
sporadically in a local region of China.
3.3. Clinical ﬁndings and laboratory examination
The incubation period (from tick bite to the appearance of
clinical symptoms) of the disease in these patients ranged from 2 to
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symptoms during the incubation period, except for seven patients
who felt weak and tired. The disease began abruptly with fever
(100%), headache (75%), anorexia (77%), muscle aches (33%),
nausea and vomiting (23%), diarrhea (31%), and other nonspeciﬁc
signs and symptoms. Fifteen patients (31%) exhibited inguinal
lymphadenectasis with incrustation and deﬁned borders, but no
rupture or necrosis.
Within a few days of onset, most patients exhibited coagulation
defects and mild hemorrhagic symptoms, such as hematuria and
ecchymosis (Figure 1), and severe cases had massive bleeding from
the gastrointestinal tract (10%) to other organs. Some patients
displayed arrhythmias, proteinuria (98%), hepatic dysfunction
(95%), and encephalopathy (48%), even with trembling, astasia, and
coma (8.3%). Thirty-ﬁve patients (73%) had hemorrhagic manifes-
tations, including one patient (2.1%) with epistaxis, bleeding gums,
and petechiae; two patients (4.2%) with vaginal hemorrhage,
hematemesis, and hemoptysis; 19 patients (39.6%) with ecchymo-
ses; 10 patients (20.8%) with melena; and 21 patients (43.8%) with
hematuria. Five patients (10.4%) suffered confusion, 17 patients
(35.4%) suffered drowsiness, and 18 patients (37.5%) had a tremor.
Therefore, most patients displayed manifestations involving
multiple organs. Of the 48 patients, many had abnormal levels
of ALT (95%) and AST (92%), but only a few patients displayed
abnormal levels of plasma total bile acid (15%). During the course
of the disease, many patients showed higher levels of plasma CK
(95%) and LDH (100%), indicative of cell death and organ
dysfunction. Almost all of the patients had a prolonged APTT
(88%) and TT (88%). More than half of the patients had elevated
blood glucose (56%), indicative of pancreatic lesions. In addition, 14
patients (29.1%) showed an abnormal electrocardiogram of sinus
bradycardia, abnormal ST segments, and/or abnormal T waves, but
no patient had abnormal ﬁndings on echocardiography.
The diversity of laboratory ﬁndings in ﬁve patients who were
admitted to the hospital during the early stage of the disease
process and who recovered fully from the illness, is shown in
Table 1. Clearly, their laboratory results changed on days 5–8 post
disease onset (p < 0.05) as compared to days 2–4 post onset. Some
of the laboratory results improved slightly on days 9–12 post onset
as compared with days 5–8 post onset (p < 0.05).
Laboratory examinations of all 48 patients with HYSV infection
on day 1 post admission are shown in Table 2. Although we knew
that the ﬁve patients who had come to the hospital during the early
stage of disease had some nonspeciﬁc symptoms within the initial
3–4 days, the laboratory test values of these patients were
signiﬁcantly different from those of the 28 patients who arrived at
the hospital on days 5–8 post disease onset (p < 0.05). However,
there was no signiﬁcant difference in the laboratory test values
between the 15 patients admitted at the later stage of disease and
the 28 patients admitted during the intermediate stage.Figure 1. Bleeding visible on the back of one patient infected with Huaiyangshan
virus.3.4. Therapeutic responses
Following treatment, we found that body temperature
decreased to the normal level within 1–5 days post treatment in
32 out of 48 patients. Furthermore, of the 26 patients with severe
neutropenia treated with G-CSF, 15 experienced a dramatic
increase in white blood cell count. Some patients with heavy
bleeding were treated with positive transfusion of platelets and
clotting factors, as well as vasopressin, somatostatin, oxytocin, and
others. Their bleeding was controlled and their blood pressure
returned to the normal range. Following treatment with positive
pressure ventilation through a breathing machine, particularly
with ECMO, patients had obvious improvements in their shortness
of breath, oxygen saturation, pulmonary edema, and ARDS. In
addition, treatment with oxygen, nutrition, cardiac drugs, and
digitalis signiﬁcantly improved the cardiac function in a few
patients with heart failure. Moreover, treatment with diuretic
drugs and/or kidney dialysis dramatically ameliorated the renal
function in 11 patients with severe kidney failure. Finally,
treatment with either liver-protecting drugs or artiﬁcial liver
support system rapidly improved the liver function in a few
patients with severe liver dysfunction.
During the convalescent period, the body temperature of most
patients gradually returned to a normal level. Their body functions
gradually recovered. Overall, 35 out of 48 patients recovered
completely and 13 patients died due to the disease severity or
severe complications, including deep coma and pulmonary fungal
infection. Stratiﬁcation of patients with or without complications
and further bivariate analysis indicated that leukocytes <2  109/l,
platelets <30  109/l, ALT >200 U/l, LDH >500 U/l, CK >400 U/l,
and creatinine >150 mmol/l were risk factors for mortality
(Table 3). Similarly, the percentage death in patients with a
complication of pulmonary infection or central nervous system
(CNS) manifestations was signiﬁcantly higher than that of those
without these complications. The severity was an independent
factor for a poor prognosis in patients with HYSHF in this
population. Multiple logistic regression analysis of eight risk
factors indicated that ‘CNS manifestations’ was an independent
factor for a poor prognosis in patients with HYSHF in this
population (p < 0.05). However, the age and gender of the patients
and their administration time were not signiﬁcantly associated
with a poor prognosis in this population (p > 0.05).
4. Discussion
VHFs are characterized by malaise, myalgia, and prostration
due to systemic abnormalities of vascular permeability and
regulation. Patients with a VHF often develop bleeding manifesta-
tions, particularly in severe cases, which are usually diffuse,
reﬂecting widespread vascular damage. While hemorrhagic fever
with renal syndrome (HFRS), CCHF, and dengue fever are common
diseases in China,9–12 HYSHF has only recently been identiﬁed.3
HYSHF was also considered as SFTS.13 We have reported the cases
of 48 patients who had a clinical history compatible with HYSHF in
a local region of Hubei and Henan provinces, Central China; these
patients were conﬁrmed to have the HYSV infection by IFA and RT-
PCR.
An epidemiological study indicated that these patients came
from rural areas of Huaiyangshan and that the virus has spread
since 2009, suggesting a sporadic nature. Most patients were older
than 40 years of age. This is different to HFRS, CCHF, and dengue
fever, which predominantly affect younger adults.14,15 It is possible
that fewer young men are now living in this region and that they
had moved into the cities for work. Alternatively, many young men
might become infected with HYSV, but have mild symptoms and
not seek medical help. No child was found to be affected, which
Table 1
Laboratory ﬁndings of ﬁve patients admitted to the hospital during the early phase of the illness
Laboratory test Days 2–4 after onset,
median (range)
Days 5–8 after onset,
median (range)
Days 9–12 after onset,
median (range)
Normal ranges
AST (U/l) 45 (32–86) 231 (89–465)a 145 (71–239) 8–40
ALT (U/l) 27 (21–57) 119 (55–358)a 78 (52–204) 5–40
Leukocytes ( 109/l) 4.42 (2.92–7.22) 2.29 (0.89–3.23)a 4.61 (2.58–6.47)a 4–10
Platelets ( 109/l) 91 (75–98) 33 (18–62)a 59 (31–87) 100–300
CK (U/l) 102 (77–180) 942 (244–3822)a 203 (127–412)a 38–174
LDH (U/l) 73 (47–105) 875 (295–3054)a 292 (195–679)a 109–225
APTT (s) 42.2 (33.7–47.2) 60.4 (49.4–71.3)a 22.8 (24.1–19.3)a 23.5–43.5
TT (s) 14.5 (11.7–17.6) 25.5 (21.1–34.2)a 18.4 (15.6–21.7) 16–20
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase; APTT, activated partial thromboplastin time; TT, thrombin
time.
a p < 0.05 vs. the ﬁrst 2–4 days, as determined by the Mann–Whitney test.
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addition, older patients with HYSV infection displayed more severe
clinical symptoms and were referred to our hospital, contributing
to the higher frequency of patients.
Given that the patients had a history of tick bite and that HYSV
has been isolated from Haemaphysalis ticks,3 this disease might be
mediated mainly by Haemaphysalis ticks. It is possible that
farmers have a greater chance of being bitten by a Haemaphysalis
tick and becoming infected. Although the person-to-person
transmission of HYSV (or SFTSV) through blood contact or personal
contact has recently been reported,6,16,17 these 48 cases occurred
sporadically in the endemic region. We did not observe any case in
a close family member of a patient with HYSHF and not a single
case occurred in the healthcare providers at the hospital who cared
for these patients. Accordingly, it is possible that these 48 cases
were infected with HYSV through a tick bite rather than by
person-to-person transmission. We are interested in further
systematically investigating how many residents are infected with
HYSV in this area and what immune responses have developed in
this population. Interestingly, recent studies have suggested that
new cases have also occurred outside the Huaiyangshan area during
the past 2 years,18–20 indicating that HYSHF has already spread
outside the Huaiyangshan area; however no case of HYSHF has been
reported in Zaoyang City, which is adjacent to Suizhou City. We are
interested in further investigating the real endemic areas and how
the HYSV spreads in these areas.
The ﬁnal diagnosis of HYSHF depends on a compatible clinical
history with laboratory evidence of HYSV infection. Because these
patients initially present nonspeciﬁc clinical symptoms and
laboratory ﬁndings, physicians may diagnose the illness as a
common ﬂu or urinary infection at the early stage of the disease
process. Although the RT-PCR-based assay is highly sensitive, we
found that nine patients with similar clinical manifestations were
negative for HYSV RNA detection, and they were diagnosed withTable 2
Laboratory results of 48 patients with Huaiyangshan virus-related hemorrhagic fever o
Laboratory test Early stage admission
(<5 days after onset)
Intermediate sta
(5–8 days after 
AST (U/l) 2/5, 45 (32–86) 27/28, 312 (38–
ALT (U/l) 2/5, 27 (21–57) 27/28, 157 (34–
Leukocytes ( 109/l) 2/5, 4.42 (2.92–7.22) 26/28, 1.90 (0.5
Platelets ( 109/l) 5/5, 91 (75–98) 27/28, 26 (4–10
CK (U/l) 1/5, 102 (77–180) 27/28, 755 (105
LDH (U/l) 0/5, 73 (47–105) 27/28, 847 (51–
APTT (s) 1/5, 42.2 (33.7–47.2) 27/28, 55.4 (35.
TT (s) 0/5, 14.5 (11.7–17.6) 27/28, 28.0 (15.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; LDH
time.
a Data shown are the ratios of cases with abnormal values to cases with normal val
b p < 0.05 vs. the early stage, as determined by the Mann–Whitney test.lymphoma, Gram-negative bacterial septicemia, and coxsackie
virus infection. However, we cannot completely exclude the
possibility of co-infection with HYSV in those patients. The false-
negative detection of HYSV may be caused by low levels of viral
RNA or a sub-optimal time for testing. Therefore, the speciﬁcity
and sensitivity of this assay for the detection of HYSV need to be
improved. Given that this was a new virus-mediated disease,
clinicians were generally unaware of the emergence of the disease
in China. Furthermore, many laboratories in small hospitals lack
the equipment and skilled personnel to test for HYSV. Hence, the
development of a new detection kit with an easier method for
clinical practice is urgently required. Although the characterization
of antibody responses, particularly a 4-fold increase in antibody
titers, is valuable,21 serological analysis is mainly used for
retrospective and epidemiological studies, and its value in the
early diagnosis has not been conﬁrmed. The in vitro isolation of
HYSV from blood or other body ﬂuids requires specialized
laboratories. This, together with the 2–6 weeks required to obtain
results,3 make this protocol unfeasible for the early diagnosis. As
we found that leukopenia, thrombocytopenia, and multiple organ
dysfunction appeared several days after the onset of the febrile
illness (Table 1), we recommend that clinicians should suspect
HYSHF and monitor the clinical laboratory tests regularly if
individuals have a history of tick bite, exposure to animals, and the
presence of relevant symptoms, particularly if the patient is an
animal handler or farmer from an endemic area.
Currently no speciﬁc treatment for HYSHF is available. We
treated all of the patients according to their clinical symptoms and
laboratory test results. We found that the surveillance of vital
signs, patient consciousness, blood cell counts, and blood
biochemistry results were the cornerstone of treatment. Because
these patients were suspected of having toxic shock syndrome,
urinary infections, meningitis, or hematological diseases at the
early stage of the disease in the local clinic, they were treated withn admissiona
ge admission
onset)
Later stage admission
(9–15 days after onset)
Normal ranges
1856)b 12/15, 212 (21–930) 8–40
955)b 14/15, 127 (36–406) 5–40
9–6.44)b 11/15, 1.84 (0.56–5.95) 4–10
2)b 15/15, 23 (5–84) 100–300
–6423)b 14/15, 735 (158–9805) 38–174
4598)b 28/28, 605 (302–11619) 109–225
5–171.8)b 10/15, 51.8 (31.9–109) 23.5–43.5
4–118.4)b 10/15, 33.1 (15.7–118.4) 16–20
, lactate dehydrogenase; APTT, activated partial thromboplastin time; TT, thrombin
ues, median values, and ranges for each measure.
Table 3
Stratiﬁcation analysis of mortality
Complication Patients with the complication Patients without the complication p-Value
Total Died % Total Died %
Bleeding manifestations 35 9 25.7 13 4 30.8 >0.05
CNS manifestations 23 9 39.1 25 4 16.0 <0.05
Creatinine >150 mmol/l 11 7 63.6 37 6 16.2 <0.05
ALT >200 U/l 14 6 42.9 34 7 20.6 <0.05
AST >200 U/l 31 10 32.3 17 3 17.6 >0.05
Platelets <30  109/l 41 13 31.7 7 0 0 <0.05
LDH >500 U/l 25 10 40.0 23 3 13.0 <0.05
CK >400 U/l 32 11 34.4 16 2 12.5 <0.05
Leukocytes <2  109/l 26 10 34.5 22 3 13.6 <0.05
Bilirubin >19 mmol/l 39 11 28.2 9 2 22.2 >0.05
Secondary pulmonary infection 15 7 46.7 33 6 18.2 <0.05
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CNS, central nervous system; CK, creatine kinase; LDH, lactate dehydrogenase.
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effect of these antibiotics on disease progression is unclear, we did
ﬁnd that ﬁve patients who were treated with high doses of
corticosteroids developed fungal infections with severe outcomes.
Thus, we do not recommend treatment with broad-spectrum
antibiotics or corticosteroids for those with undiagnosed disease,
particularly those suspected of having HYSHF, even if the patients
have encephalopathy and arrhythmias, because many older
patients with HYSHF were immunocompromised with progressive
leukopenia. More importantly, high virus loads are correlated with
systemic cytokine storm and a poor prognosis.17,22We suspect that
the use of corticosteroids may impede the clearance of HYSV in
patients. Finally, treatment with broad-spectrum antibiotics and
corticosteroids did not help to relieve the encephalopathy or to
shorten the course of disease in those patients.
Patients were diagnosed with ehrlichiosis in April 2009 at our
hospital.23 Because of the great similarity in the clinical symptoms
and laboratory examination results of patients with HYSHF and
those with ehrlichiosis,23,24 we had considered some patients as
having ehrlichiosis in 2009 before HYSV was identiﬁed. Interest-
ingly, we found that treatment with doxycycline reduced body
temperature within a couple days post medication and improved
clinical symptoms and laboratory values as well, consistent with a
recent report.25 One possible reason for this is that treatment with
doxycycline controlled a secondary bacterial infection in those
patients who had leukopenia and poor immunity. Because
antibiotics should have no effect on the control of a viral infection,
further studies are needed to clarify the efﬁcacy of treatment with
doxycycline in patients with HYSHF.
In summary, we have described the characteristics of clinical
symptoms, laboratory examinations, primary epidemiological
factors, and therapeutic responses of 48 patients with HYSHF.
Because patients with HYSHF displayed clinical symptoms similar
to those of other diseases, it is crucial for clinicians to recognize and
be aware of the recent emergence of this new disease in China.
Individuals with a history of tick bite, exposure to animals, and the
presence of a symptom complex compatible with HYSV infection
should be suspected of HYSHF. We found that, once a patient was
suspected with HYSHF, she/he should be treated immediately and
closely monitored because of rapid progression of this disease. We
do not recommend treatment of these patients with broad-
spectrum antibiotics and corticosteroids, which may cause severe
fungus infections. We are interested in further investigating the
pathogenic process of the disease and the therapeutic values of
available treatments to reduce the mortality. Epidemiologically,
we need to identify the infectious sources, the transmission routes
of the disease, the sub-clinical infection rate in the population in
the endemic area, and the potential strategies for the prevention of
HYSV infection.Acknowledgement
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